



Drug Quantity Management – Per Days Dermatology – Vtama® (tapinarof 1% cream)

Table of Contents

National Formulary Medical Necessity	1
Conditions Not Covered.....	2
Background.....	2
References	2
Revision History.....	2

Product Identifier(s)

Effective 1/1/23 to 4/11/23: 109857
Effective 4/12/23: 106692

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Vtama. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Drug Quantity Limits

Product	Strength and Form	Retail Maximum Quantity per 30 Days	Home Delivery Maximum Quantity per 90 days
Vtama® (tapinarof 1% cream)	60 gram tube	1 tube (60 grams)	3 tubes (180 grams)

Cigna covers quantities as medically necessary when the following criteria are met:

1. If an individual needs to treat greater than 8% of their body surface area, approve the requested quantity, not to exceed 180 grams (3 tubes) per 30 days at retail and 540 grams (3 tubes) at home delivery.

Conditions Not Covered

Any other exception is considered not medically necessary.

Background

Overview

Vtama, an aryl hydrocarbon receptor agonist, is indicated for the topical treatment of **plaque psoriasis** in adults.¹

Dosing

Apply a thin layer of Vtama to the affected area(s) once daily (QD).¹ The pivotal studies enrolled patients with plaque psoriasis, with a body surface area involvement of 3% to 20%.

Availability

Vtama is available as a 1% cream, supplied in 60 g tubes.¹

Application Information

For topical product application, a standard measure, the finger-tip unit (FTU), is often used.² One FTU is the amount of product that is squeezed out of a standard tube along an adult's fingertip. One FTU is equivalent to approximately 0.5 g and provides enough product to treat an area of skin that is twice the size of one adult hand, or approximately 2% of an adult's total body surface area (BSA). Therefore, it is assumed that 2 g of a topical agent would provide enough product for one application to approximately 8% of the patient's BSA. Based on the FTU method, the quantity limits of 60 g per 30 days are estimated to provide enough Vtama to cover approximately 8% of the patient's BSA when applying QD for 1 month (30 days).

References

1. Vtama® topical cream [prescribing information]. Long Beach, CA: Dermavant; May 2022.
2. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. *J Am Acad Dermatol.* 2009;60(4):643-659.

Revision History

Type of Revision	Summary of Changes	Approval Date
New Policy	--	06/08/2022
Selected Revision	Override for a patient who needs to treat greater than 8% of their body surface area was changed to approve the requested quantity, not to exceed 180 grams (3 tubes) per 30 days at retail and 540 grams (3 tubes) at home delivery. Previously, this override approved a quantity not to exceed 120 grams (2 tubes) per 30 days at retail at 360 grams (6 tubes) at home delivery.	08/17/2022

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc. and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2023 Cigna.